137 related articles for article (PubMed ID: 36774655)
21. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
22. Assessing Lysine and Cysteine Reactivities for Designing Targeted Covalent Kinase Inhibitors.
Liu R; Yue Z; Tsai CC; Shen J
J Am Chem Soc; 2019 Apr; 141(16):6553-6560. PubMed ID: 30945531
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
Zhang T; Hatcher JM; Teng M; Gray NS; Kostic M
Cell Chem Biol; 2019 Nov; 26(11):1486-1500. PubMed ID: 31631011
[TBL] [Abstract][Full Text] [Related]
24. Lysine-Reactive
Kawano M; Murakawa S; Higashiguchi K; Matsuda K; Tamura T; Hamachi I
J Am Chem Soc; 2023 Dec; 145(48):26202-26212. PubMed ID: 37987622
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic Investigation of Lysine-Targeted Covalent Inhibition of PI3Kδ via ONIOM QM:QM Computations.
Fındık V; Varınca Gerçik BT; Sinek Ö; Erdem SS; Ruiz-López MF
J Chem Inf Model; 2022 Dec; 62(24):6775-6787. PubMed ID: 35980989
[TBL] [Abstract][Full Text] [Related]
26. Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.
Zhang Y; Zhang D; Tian H; Jiao Y; Shi Z; Ran T; Liu H; Lu S; Xu A; Qiao X; Pan J; Yin L; Zhou W; Lu T; Chen Y
Mol Pharm; 2016 Sep; 13(9):3106-18. PubMed ID: 27483186
[TBL] [Abstract][Full Text] [Related]
27. The Cysteinome of Protein Kinases as a Target in Drug Development.
Chaikuad A; Koch P; Laufer SA; Knapp S
Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
[TBL] [Abstract][Full Text] [Related]
28. Multitarget inhibitors/probes that target LRRK2 and AURORA A kinases noncovalently and covalently.
Wang W; Wang X; Tang G; Zhu C; Xiang M; Xiao Q; Zhang ZM; Gao L; Yao SQ
Chem Commun (Camb); 2023 Sep; 59(72):10789-10792. PubMed ID: 37594149
[TBL] [Abstract][Full Text] [Related]
29. An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.
D'Ascenzio M; Pugh KM; Konietzny R; Berridge G; Tallant C; Hashem S; Monteiro O; Thomas JR; Schirle M; Knapp S; Marsden B; Fedorov O; Bountra C; Kessler BM; Brennan PE
Angew Chem Int Ed Engl; 2019 Jan; 58(4):1007-1012. PubMed ID: 30589164
[TBL] [Abstract][Full Text] [Related]
30. Protein kinase inhibitors: contributions from structure to clinical compounds.
Johnson LN
Q Rev Biophys; 2009 Feb; 42(1):1-40. PubMed ID: 19296866
[TBL] [Abstract][Full Text] [Related]
31. Lysine-Targeted Inhibitors and Chemoproteomic Probes.
Cuesta A; Taunton J
Annu Rev Biochem; 2019 Jun; 88():365-381. PubMed ID: 30633551
[TBL] [Abstract][Full Text] [Related]
32. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
Zhou W; Ercan D; Chen L; Yun CH; Li D; Capelletti M; Cortot AB; Chirieac L; Iacob RE; Padera R; Engen JR; Wong KK; Eck MJ; Gray NS; Jänne PA
Nature; 2009 Dec; 462(7276):1070-4. PubMed ID: 20033049
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking.
Wan X; Yang T; Cuesta A; Pang X; Balius TE; Irwin JJ; Shoichet BK; Taunton J
J Am Chem Soc; 2020 Mar; 142(11):4960-4964. PubMed ID: 32105459
[TBL] [Abstract][Full Text] [Related]
34. Irreversible protein kinase inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
[TBL] [Abstract][Full Text] [Related]
35. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
36. Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors.
Dittus L; Werner T; Muelbaier M; Bantscheff M
ACS Chem Biol; 2017 Oct; 12(10):2515-2521. PubMed ID: 28876896
[TBL] [Abstract][Full Text] [Related]
37. Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα.
Borsari C; Keles E; McPhail JA; Schaefer A; Sriramaratnam R; Goch W; Schaefer T; De Pascale M; Bal W; Gstaiger M; Burke JE; Wymann MP
J Am Chem Soc; 2022 Apr; 144(14):6326-6342. PubMed ID: 35353516
[TBL] [Abstract][Full Text] [Related]
38. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
39. Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.
Park KS; Xiong Y; Yim H; Velez J; Babault N; Kumar P; Liu J; Jin J
J Med Chem; 2022 Aug; 65(15):10506-10522. PubMed ID: 35763668
[TBL] [Abstract][Full Text] [Related]
40. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
Roskoski R
Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
